Nutritional compositions and infant formula for promoting de novo myealination
AssigneeSociete des Produits Nestle S.A.
InventorsNora Schneider, Jonas Hauser, Sean Deoni, Tamas Bartfai
Life of this patent
Estimating the term…
Abstract
A synthetic nutritional composition comprising a mineral for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.
Claims11
A method for promoting, supporting or optimizing de novo myelination, the method comprising administering, to a formula fed infant having a suboptimal de novo myelination trajectory, a synthetic nutritional composition comprising greater than 4 mg of iron/100 g dry weight of the synthetic nutritional composition.
A method for promoting, supporting or optimizing an outcome selected from the group consisting of de novo myelination trajectory, brain structure, brain connectivity, intellectual potential, cognitive potential, learning potential, cognitive functioning, and combinations thereof in a human formula fed infant having a suboptimal de novo myelination trajectory, the method comprising administering a synthetic nutritional composition comprising greater than 4 mg of iron/100 g dry weight of the synthetic nutritional composition to the human formula fed infant having a suboptimal de novo myelination trajectory, and wherein brain structure refers to the amount and/or spatial distribution of myelinated matter throughout the brain, and/or in specific brain regions, and wherein the cognitive function is optimised if the human formula fed infant has scores in a standardized neurodevelopmental test that are less than one standard deviation different from that of an exclusively breastfed subject of a well-nourished mother.
Dependencies are inferred from the claim text.